• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by DocGo Inc.

    11/29/24 4:14:57 PM ET
    $DCGO
    Medical/Nursing Services
    Health Care
    Get the next $DCGO alert in real time by email
    SC 13D/A 1 schedule13da-svashovsky.htm SC 13D/A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13D

    (Amendment No. 1)*

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    DOCGO INC.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    256086 109
    (CUSIP Number)

    35 West 35th Street, Floor 6
    New York, New York 10001
    (844) 443-6246
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 15, 2022
    (Date of Event Which Requires Filing of Statement on Schedule 13D)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), checking the following box. ☐
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Schedule 13D

    CUSIP No. 256086109
    (1)
    Name of Reporting Persons:
    Stanley Vashovsky
    (2)
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a) ☐ (b) ☐
    (3)
    SEC Use Only:
    (4)
    Source of Funds (See Instructions):
    OO
    (5)
    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):
    ☐
    (6)
    Citizenship or Place of Organization:
    United States



    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    (7)
    Sole Voting Power
    5,908,447 (as of November 27, 2024)(1)(2) and 10,465,695 (as of December 15, 2022)(1)(3)
    (8)
    Shared Voting Power
    0
    (9)
    Sole Dispositive Power
    5,908,447 (as of November 27, 2024)(1)(2) and 10,465,695 (as of December 15, 2022)(1)(3)
    (10)
    Shared Dispositive Power
    0
    (11)
    Aggregate Amount Beneficially Owned by Each Reporting Person:
    5,908,447 (as of November 27, 2024)(1)(2) and 10,465,695 (as of December 15, 2022)(1)(3)
    (12)
    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
    ☐
    (13)
    Percent of Class Represented by Amount in Row (11):
    5.8% (as of November 27, 2024)(4) and 10.2% (as of December 15, 2022)(5)
    (14)
    Type of Reporting Person (See Instructions):
    IN

    (1)
    The inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of this Schedule 13D or for any other purpose.
    (2)
    Includes 764,199 shares of Common Stock underlying stock options that are exercisable as of November 27, 2024 or will become exercisable within 60 days of such date, which include the shares described in footnote 3 below.
    (3)
    Includes 254,733 shares of Common Stock underlying stock options exercisable as of December 15, 2022.
    (4)
    Based on 101,526,981 shares of Common Stock outstanding as of November 27, 2024.
    (5)
    Based on 102,411,162 shares of Common Stock outstanding as of December 15, 2022.


    EXPLANATORY NOTE

    This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D (as amended, the “Schedule 13D”) is filed by Stanley Vashovsky (“Mr. Vashovsky”) and amends the initial statement on Schedule 13D filed by Mr. Vashovsky on November 15, 2021 (the “Original Filing”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Original Filing. Capitalized terms used but not defined have the meaning given them in the Original Filing.

    ITEM 1. SECURITY AND ISSUER

    Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    This Schedule 13D relates to shares of common stock, par value $0.0001 per share (the “Common Stock”), of DocGo Inc., a Delaware corporation (f/k/a Motion Acquisition Corp.) (the “Company”).

    The address of the Company’s principal executive offices is 35 West 35th Street, Floor 6, New York, New York 10001.

    ITEM 2. IDENTITY AND BACKGROUND

    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:




    (a)
    This Schedule 13D is being filed by Stanley Vashovsky, an individual.

    (b)
    The principal business address of Mr. Vashovsky is 35 West 35th Street, Floor 6, New York, New York 10001.

    (c)
    Mr. Vashovsky’s principal occupation is serving as a consultant.

    (d)During the last five years, Mr. Vashovsky has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e)During the last five years, Mr. Vashovsky has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f)Mr. Vashovsky is a United States citizen.

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    Mr. Vashovsky received 13,160,962 shares of Common Stock pursuant to the Merger Agreement as consideration for his securities held in Ambulnz.

    On December 9, 2021, in connection with his service as Chief Executive Officer of the Company, Mr. Vashovsky received a grant under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”) of options to purchase 1,018,932 shares of Common Stock (the “Options”). Of such Options, 25% vested and became exercisable on December 9, 2022 and 25% vested and became exercisable on December 9, 2023. The remaining Options vest and become exercisable in two equal installments on December 9, 2024 and December 9, 2025.

    On March 16, 2023, for his prior service as Chief Executive Officer of the Company, Mr. Vashovsky received a grant under the Plan of 127,379 fully vested shares of Common Stock in lieu of his 2022 annual cash bonus, net of shares withheld for taxes and other payroll withholdings.

    On May 12, 2023, November 10, 2023, December 12, 2023 and March 15, 2024, Mr. Vashovsky received grants under the Plan of 9,234, 27,797, 15,307 and 21,721 fully vested shares of Common Stock, respectively, each as compensation for his service as non-executive Chair of the Company’s Board of Directors (the “Board”).

    On August 19, 2024 and November 14, 2024, Mr. Vashovsky received grants under the Plan of 19,886 and 8,373 shares of Common Stock, respectively, as compensation for his services under the Consulting Agreement (as defined in Item 6 hereto). The information set forth under Item 6 hereto with respect to the Consulting Agreement is incorporated by reference herein.

    Except as described above in this Item 3, Mr. Vashovsky did not pay any cash or other consideration for his securities in the Company.
    ITEM 4. PURPOSE OF TRANSACTION

    Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    Mr. Vashovsky acquired securities described in this Schedule 13D for investment purposes. Mr. Vashovsky expects to evaluate on an ongoing basis the Company’s financial condition and prospects and his interest in, and



    intentions with respect to, the Company and its investment in the securities of the Company. This evaluation may be based on various factors, including but not limited to the Company’s business and financial condition, results of operations and prospects, general market, economic and industry conditions, the securities markets in general and those for the Company’s securities in particular, as well as other developments and other investment opportunities. Accordingly, Mr. Vashovsky reserves the right to change his intentions and develop plans or proposals at any time, as he may deem appropriate. Subject to certain restrictions contained in the Company’s Insider Trading Policy, Mr. Vashovsky may from time to time acquire or dispose of all or a portion of securities of the Company as appropriate for his personal circumstances.

    In connection with or through Mr. Vashovsky’s service as a consultant to the Company or otherwise, Mr. Vashovsky may engage in discussions with management, members of the Board, other stockholders of the Company and other relevant parties concerning the operations, management, composition of the Board and management, ownership, capital structure, strategy, and future plans of the Company, including the possibility of proposing one or more acquisitions, business combinations, mergers, asset sales, asset purchases, or other similar transactions to be executed by or otherwise involving the Company and other third parties. As a result, Mr. Vashovsky may take positions with respect to and seek to influence the decision of the Board regarding the matters discussed above. Such suggestions or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported herein. Such actions may involve one or more of the events referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D.

    ITEM 5. INTEREST IN SECURITIES OF THE COMPANY

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a), (b) The information relating to the beneficial ownership of Common Stock by Mr. Vashovsky set forth in Rows 7 through 13 of the cover page hereto and the related footnotes are incorporated by reference herein. Mr. Vashovsky also holds Options to purchase an additional 254,733 shares of Common Stock, which will vest and become exercisable on December 9, 2025; the shares of Common Stock underlying these Options are not reflected in the beneficial ownership information set forth in Rows 7 through 13 of the cover page hereto and the related footnotes, as they are not exercisable within 60 days of November 27, 2024.

    (c) The information set forth under Item 3 hereto is incorporated by reference herein.

    In addition, on December 15, 2022, Mr. Vashovsky gifted 1,746,723 shares of Common Stock to a trust for estate planning purposes and 1,203,277 shares of Common Stock to a charitable trust, in each case with no beneficial ownership retained.

    On May 15, 2023, Mr. Vashovsky gifted 1,500,000 shares of Common Stock to a trust for estate planning purposes with no beneficial ownership retained.

    On August 15, 2023, Mr. Vashovsky gifted 1,200,000 shares of Common Stock to a trust for estate planning purposes with no beneficial ownership retained.

    On November 27, 2024, Mr. Vashovsky gifted 2,596,511 shares of Common Stock to a trust for estate planning purposes with no beneficial ownership retained.

    (d) None.

    (e) Not applicable.
    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE COMPANY

    Item 6 of the Schedule 13D is hereby amended to add the following after the second paragraph:

    Consulting Agreement – On March 7, 2024, Mr. Vashovsky entered into a separation and consulting agreement with the Company (the “Consulting Agreement”), pursuant to which Mr. Vashovsky agreed to continue to serve as a consultant to the Company until March 31, 2025 (such period, the “Consulting Period”). Pursuant to the



    Consulting Agreement, Mr. Vashovsky will provide advisory services as may be requested from time to time by the Company’s executive officers or the Board and assist with maintaining the Company’s existing customer and investor relationships and, as consideration for his services, receive an equity grant during each quarter of the Consulting Period having a grant date fair value of approximately $35,000. In consideration for a release of claims, Mr. Vashovsky will also be eligible to receive Company-subsidized healthcare coverage for the duration of the Consulting Period. The Consulting Agreement further acknowledges and affirms that Mr. Vashovsky will be bound by and comply with certain restrictive covenants.

    The foregoing description of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the Consulting Agreement, a copy of which is filed herewith as Exhibit 7.3.

    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

    Item 7 of the Schedule 13D is hereby amended to add the following:

    7.3
    Separation and Consulting Agreement, dated March 7, 2024, by and between the Company and Mr. Vashovsky (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on March 8, 2024).
    7.4
    Form of Grant Notice for Nonqualified Stock Options and Standard Terms and Conditions for Nonqualified Stock Options under the DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2023).

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this Schedule 13D is true, complete, and correct.

    Dated as of November 29, 2024

    By:
    /s/ Stanley Vashovsky
    Name:
    Stanley Vashovsky


    Get the next $DCGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCGO

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    2/28/2025$5.00 → $2.85Buy → Hold
    Deutsche Bank
    8/18/2023$15.00Buy
    BTIG Research
    4/21/2023$11.00Overweight
    Cantor Fitzgerald
    4/19/2022$11.00Buy
    Deutsche Bank
    1/19/2022$14.00Buy
    Stifel
    12/21/2021$13.00Buy
    Canaccord Genuity
    12/7/2021$14.00Buy
    Needham
    More analyst ratings

    $DCGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DocGo Announces First Quarter 2025 Results

      Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended March 31, 2025. Lee Bienstock, Chief Executive Officer of DocGo, commented, "The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Populati

      5/8/25 4:05:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo to Announce First Quarter Results on Thursday, May 8, 2025

      Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31st, 2025 after the markets close on Thursday, May 8th, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Thursday, May 8th, 2025 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 65854 To access the Call me™ feature, which avoids the need to wait for an operator, click https:

      4/21/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Earns Great Place To Work Certification™ For the Third Time in a Row

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced that it has been Certified™ by Great Place To Work® for the third time in a row. This prestigious award is based on what current employees say about their experience working at the Company. This year, employees rated DocGo 31% higher than the average US company as a Great Place to Work. Great Place To Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. "Our clinicians who bring care to patients where they need it – and the

      3/31/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Leadership Updates

    Live Leadership Updates

    See more
    • DocGo Acquires PTI Health To Expand Proactive Healthcare Offering with Mobile Lab Collection and Mobile Phlebotomy Services

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced the acquisition of PTI Health, a mid-Atlantic mobile lab collection and phlebotomy services company. This strategic move expands DocGo's healthcare service offering to include mobile phlebotomy lab services, addressing critical gaps in diagnostic care for underserved populations. With this acquisition, DocGo will facilitate timely, convenient blood collection and additional at-home testing services for patients, offering a new level of care to those with limited access to traditional labs or transportation options. The acquisition enhances DocGo's offerings

      2/10/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced the appointment of Stephen K. Klasko, M.D., M.B.A as the new independent, non-executive Chair of its Board of Directors, effective October 1, 2024. Dr. Klasko has an extensive background in leadership roles within healthcare, higher education and medical industry innovation, including an eight-year tenure as the President of Thomas Jefferson University and the CEO of Jefferson Health where he oversaw its expansion to 18 hospitals and over 35,000 employees. Prior to that, he was CEO of USF Health and Dean of the Morsani College of Medicine at the University o

      9/30/24 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Appoints Eiwe Lingefors as New Chief Information Officer

      DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-driven healthcare solutions, is proud to announce Eiwe Lingefors as Chief Information Officer (CIO). Lingefors most recently served as the company's Chief Information Security Officer, and will continue in this role as well. In his new role as CIO, Lingefors will lead both DocGo's information security and digital innovation strategy in an evolving cybersecurity landscape. "Eiwe has been a vital part of our team, and his deep expertise in the security landscape has been instrumental in DocGo's operations," said Lee Bienstock, CEO of DocGo. "He has done an excellent job strengthening DocGo's existing cybers

      9/26/24 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DCGO
    Financials

    Live finance-specific insights

    See more
    • Burdiek Michael J bought $34,000 worth of shares (10,000 units at $3.40), increasing direct ownership by 2% to 581,595 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/14/24 4:10:44 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Tendler Ely D bought $31,300 worth of shares (10,000 units at $3.13), increasing direct ownership by 7% to 162,933 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/13/24 4:34:19 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Bienstock Lee bought $78,750 worth of shares (25,000 units at $3.15), increasing direct ownership by 2% to 1,220,845 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      5/13/24 4:30:30 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Announces First Quarter 2025 Results

      Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the quarter ended March 31, 2025. Lee Bienstock, Chief Executive Officer of DocGo, commented, "The impact of ongoing policy changes in Washington and adjustments to public spending on healthcare-related projects have created substantial uncertainty in our Government Populati

      5/8/25 4:05:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo to Announce First Quarter Results on Thursday, May 8, 2025

      Management to host conference call and webcast at 5:00 p.m. ET on that day DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the first quarter ended March 31st, 2025 after the markets close on Thursday, May 8th, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day. Conference call and webcast details: Thursday, May 8th, 2025 5:00 p.m. ET 1-800-717-1738 (U.S.) 1-646-307-1865 (international) Conference ID: 65854 To access the Call me™ feature, which avoids the need to wait for an operator, click https:

      4/21/25 7:35:00 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Announces Fourth Quarter and Full-Year 2024 Results

      Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter and full-year ended December 31, 2024. Full-Year 2024 Financial Highlights Full-year 2024 revenue was $616.6 million, compared to $624.2 million for the full-year 2023. GAAP gross margin (which includes non-cash depreciation expenses) for the full-year 2024 was 32.1%, compared to 28.7%

      2/27/25 4:11:00 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DocGo downgraded by BTIG Research

      BTIG Research downgraded DocGo from Buy to Neutral

      5/9/25 8:41:42 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DocGo from Buy to Hold and set a new price target of $2.85 from $5.00 previously

      2/28/25 8:51:46 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • BTIG Research initiated coverage on DocGo with a new price target

      BTIG Research initiated coverage of DocGo with a rating of Buy and set a new price target of $15.00

      8/18/23 7:24:03 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Compliance Officer Sugrue Stephen covered exercise/tax liability with 5,614 shares, decreasing direct ownership by 2% to 347,328 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:45:15 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • CFO and Treasurer Rosenberg Norman covered exercise/tax liability with 8,004 shares, decreasing direct ownership by 0.93% to 856,272 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:44:31 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Bienstock Lee covered exercise/tax liability with 37,340 shares, decreasing direct ownership by 2% to 1,956,079 units (SEC Form 4)

      4 - DocGo Inc. (0001822359) (Issuer)

      4/2/25 4:43:52 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by DocGo Inc.

      SC 13D/A - DocGo Inc. (0001822359) (Subject)

      11/29/24 4:14:57 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by DocGo Inc.

      SC 13G/A - DocGo Inc. (0001822359) (Subject)

      11/14/24 9:56:36 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by DocGo Inc. (Amendment)

      SC 13G/A - DocGo Inc. (0001822359) (Subject)

      3/1/24 4:53:15 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care

    $DCGO
    SEC Filings

    See more
    • SEC Form 10-Q filed by DocGo Inc.

      10-Q - DocGo Inc. (0001822359) (Filer)

      5/8/25 4:35:04 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • DocGo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DocGo Inc. (0001822359) (Filer)

      5/8/25 4:15:49 PM ET
      $DCGO
      Medical/Nursing Services
      Health Care
    • SEC Form SCHEDULE 13G filed by DocGo Inc.

      SCHEDULE 13G - DocGo Inc. (0001822359) (Subject)

      4/30/25 10:53:25 AM ET
      $DCGO
      Medical/Nursing Services
      Health Care